Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
about
Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation modelsDose schedule optimization and the pharmacokinetic driver of neutropeniaPharmacodynamic model for chemotherapy-induced anemia in rats.Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.Romiplostim dose response in patients with immune thrombocytopenia.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsAre population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.Romiplostim dose-response in patients with myelodysplastic syndromesPKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
P2860
Q27015861-FE115FF4-EAB9-4AF9-B54B-C2A1A12547C1Q28544635-52000FC7-2931-406D-86B9-BADD241D0AA8Q33376775-8E21555E-D3E6-406D-BF4C-2C776575B178Q33380427-3F783BCF-3443-4687-90EC-56E143A55825Q33398730-E1DF062C-BC89-4979-A5B2-4A9776B30890Q33402778-D69EC3CC-E83D-403E-A763-9400453C1E9AQ33415594-BACDBEDF-579D-4277-9809-F0D0E3D7334EQ34580659-A655DE11-734B-474B-87A0-FB4519657A64Q34953673-C6436450-7FCD-48D6-88C1-BC5A8958AF64Q35178048-47180588-40B4-4850-B557-F1CFE42F63CEQ36344679-DA2E0F75-51DB-45C1-83E6-1CB9395BBDF0Q36747438-B917E7EE-6B62-45D6-B687-DB15FD42074AQ36948110-1E0A08EF-D012-4231-A240-70AEDC87A2A2Q37405613-9E6E4D9B-41D8-45A3-8E66-965F8680F5FBQ38289581-6363B048-6495-4C12-A9B6-823476F6471FQ40004718-DD8E5D3F-4790-4078-85B4-2480E836A563Q42170353-F01AF8A5-29C6-4BE8-8FCB-EFC786CEFAF1Q46792354-B3748637-EEE5-425C-87EC-C9106ED0A7A2Q51749848-3C2396E8-2B1F-4934-B802-E3AB4866D511
P2860
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@ast
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@en
type
label
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@ast
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@en
prefLabel
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@ast
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@en
P2093
P1476
Semi-physiological model descr ...... e anti-cancer agent indisulam.
@en
P2093
Alwin D R Huitema
Anthe S Zandvliet
Charlotte van Kesteren
Christian Dittrich
Cornelis J A Punt
Eric Raymond
Henri H Roché
Herlinde Dumez
Jan H M Schellens
Jantien Wanders
P2888
P304
P356
10.1007/S10637-005-6730-3
P577
2005-06-01T00:00:00Z
P6179
1012725203